ReNeuron Company Profile

09:05 EST 10th December 2018 | BioPortfolio

ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.


Europoint Centre , 5-11 Lavington Street
United Kingdom


Phone: 0207 928 1720
Fax: 0207 261 0268

News Articles [16 Associated News Articles listed on BioPortfolio]

ReNeuron Group (RENE) - US exclusivity deal - more than non-dilutive cash

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron ended FY18 with a healthy cash balance and the 11 July announcement of an exclusivity agreement worth up to US$5m wi...

ReNeuron Group (RENE) - Exosomes rise further

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s capital markets day highlighted the potential for the company’s exosome nanomedicine platform to be a ...

ReNeuron to resume discussions with other potential suitors as US pharma group backs out

The unnamed group’s decision not to progress to a definitive licensing agreement had nothing to do with ReNeuron’s technology, the company said

ReNeuron pens deal with undisclosed spec pharmaco

ReNeuron Group PLC licensed an undisclosed US specialty pharmaco exclusive global rights (excluding China) to its human retinal progenitor cells (hRPC) technology and therapeutic programs.

ReNeuron’s CTX stem cell platform could be used to fight cancer

ReNeuron thinks CTX could be reprogrammed and used to produce new non-donor-specific cell lines, including NK and T-Cells – the cells that can be modified to attack cancer cells

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Mich...

'All systems go' with ReNeuron Group Plc looking to treat first PISCES III patient shortly

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE), tells Proactive's Andrew Scott a Phase IIb clinical trial of their potentially breakthrough CTX cell treatment for stroke will...

Breakthrough to open up potential new revenue opportunities for Reneuron Plc

Michael Hunt, CFO at Reneuron Plc (LON:RENE), spoke to Proactive ahead of new data being presented at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) relating to it...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.

ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. We are also leveraging our ste...

More Information about "ReNeuron" on BioPortfolio

We have published hundreds of ReNeuron news stories on BioPortfolio along with dozens of ReNeuron Clinical Trials and PubMed Articles about ReNeuron for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ReNeuron Companies in our database. You can also find out about relevant ReNeuron Drugs and Medications on this site too.

Quick Search


Relevant Topics

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record